← Ultherapy

Does Ultherapy Melt Fat

Written & medically reviewed by the Dermapedia team
At a Glance

No. Ultherapy is not a fat treatment, and fat is not mentioned anywhere in what it is authorised to do.

It is micro-focused ultrasound. Sound energy is focused to a point beneath the surface, the way a magnifying glass focuses sunlight, and that point can sit as deep as the SMAS - the deep fibrous support layer under the face. The skin surface is never broken.

What it is authorised for is lifting. Its US authorisation names lifting the eyebrow, lifting lax tissue under the chin and on the neck, and improving lines and wrinkles of the decollete. A 2025 clearance added the appearance of skin laxity on the abdomen and arms. Not one of those phrases is about fat.

Loss of facial volume after energy-based tightening is discussed, and it is not well quantified. Subcutaneous fat atrophy is a documented rare adverse event of focused ultrasound, and of other tightening devices. But it is an unwanted effect, not the way the treatment works, and there is no published figure for how often it happens after focused ultrasound.

If the thing bothering you is a fat pocket rather than loose skin, this is the wrong tool. Cryolipolysis and deoxycholic acid injection are the treatments that actually name fat in their approved wording. They are a different job, not a better one.

Key Facts

What it isMicro-focused ultrasound, delivered through intact skin - nothing breaks the surface
What it is authorised to doLift the eyebrow, lift lax tissue under the chin and on the neck, improve lines and wrinkles of the decollete
Added in February 2025Improving the appearance of skin laxity on the abdomen and the front and back of the arms
Fat in the authorised wordingNot mentioned - no Ultherapy indication names fat, lipolysis or fat reduction
Regulatory routeA De Novo authorisation granted in September 2009, which created the FDA device category for this technology
Depths reachedTransducers focus at roughly 1.5 mm, 3.0 mm and 4.5 mm; the deepest reaches the SMAS, the fibrous support layer under the face
Fat loss afterwardsDocumented as a rare adverse event, not an intended effect, with no published incidence figure
If your concern is a fat pocketCryolipolysis and deoxycholic acid injection are the treatments whose authorised wording names fat
Deoxycholic acid indicationImprovement in moderate to severe convexity or fullness associated with submental fat in adults

What Ultherapy is actually aimed at

An ultrasound transducer focuses sound energy to a point below the surface. At that point tissue reaches temperatures high enough to coagulate collagen - roughly 60 to 70 degrees Celsius - leaving tiny columns of denatured collagen. Everything between the transducer and that focal point is spared, including the outer skin.

Three focal depths are used, identified in the FDA paperwork by the transducer naming convention: about 1.5 mm, 3.0 mm and 4.5 mm. The deepest of the three is what makes the device distinctive, because 4.5 mm reaches the SMAS - the fibrous support layer beneath the face. Needle-based devices generally do not reach it.

Ultherapy is also the one device in this group with real-time imaging built in, so the operator can see the tissue plane before firing. The authorised purpose of that imaging is stated plainly: to confirm the transducer is properly coupled to the skin, and to confirm the depth of treatment so as to avoid bone.

Every part of that mechanism is about heating and contracting connective tissue. None of it is about removing fat.

What the authorisation actually says

Ultherapy began as a De Novo authorisation - DEN080006, granted 11 September 2009 - which created a whole new device category for focused ultrasound in aesthetics. The exact wording of that 2009 document could not be retrieved from the FDA archive, so the first wording that can be quoted from a primary source is the 2012 clearance.

The indications, as they stand, cover lifting the eyebrow, lifting lax tissue beneath the chin and on the neck, and improving lines and wrinkles of the decollete. A February 2025 clearance added skin laxity on the abdomen and the front and back of the arms, under a general statement that the system is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin.

Fat, lipolysis, fat reduction and contouring appear nowhere. That matters for a practical reason: if a clinic tells you the treatment will slim your face or shrink a double chin, they are describing something the device has never been authorised to do.

One more piece of context. A clearance or an authorisation is a marketing permission, not a certificate that a treatment works well. It says the device met a regulatory standard for its stated purpose - nothing more.

The volume loss question, honestly

Some people describe looking thinner or more hollow after energy-based tightening, and this comes up often enough to deserve a straight answer rather than a denial.

Subcutaneous fat atrophy is listed among the rare documented adverse events of focused ultrasound, alongside transient injury to the motor nerves of the face. The same rare event is documented for monopolar radiofrequency tightening. So the phenomenon is recognised across heat-based tightening, not invented online.

Here is the limit of what can be said. There is no published figure for how often facial fat loss occurs after focused ultrasound. No incidence rate, no case series quantifying it, no data on whether it recovers. Anyone who gives you a percentage is making it up.

For context from a neighbouring device class: in an analysis of FDA postmarket reports about radiofrequency microneedling covering 2013 to 2025, fat loss made up 26 of 224 reported events. That is a different technology, and the number is a proportion of the reports that were filed, with no denominator - nobody knows how many treatments those reports came from, so it cannot be turned into a chance that something happens to you. It is evidence that the concern is real and discussed, not a risk figure.

The fair summary: unwanted volume loss after tightening treatments is a documented, unquantified risk - and it is the opposite of a selling point.

If your problem is fat, not laxity

Working out which one you have is the whole question, and it is worth asking your provider directly. Loose skin and a fat pocket look similar in a mirror and respond to completely different tools.

These are the treatments whose approved wording actually names fat. They are listed as different tools for a different problem, not as recommendations.

  • Cryolipolysis (CoolSculpting). A cooling applicator holds a fold of tissue cold enough that fat cells are damaged while skin, nerve and vessel are not, and the fat layer thins over the following weeks. Its indication is cold-assisted lipolysis - the breakdown of fat - across named areas including the abdomen, flanks, thigh, arm and back, in people with a body mass index of 30 or less, with the area under the chin indicated separately. Nothing is done to the dermis, so it does not tighten skin. Its characteristic complication is paradoxical adipose hyperplasia, a firm enlargement of the treated fat pad that does not resolve on its own; a 2025 systematic review and meta-analysis of 28 studies and 13,078 patients put the pooled incidence at 0.22 per cent, roughly 1 in 455 patients, graded low-certainty, against a manufacturer-quoted figure of 0.025 per cent.
  • Deoxycholic acid injection (Kybella). A drug, not a device, approved in 2015 under a full drug approval rather than a device clearance - a higher regulatory bar. Its indication is improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults, and its label states plainly that use outside the submental region has not been established and is not recommended. It has real downtime - swelling, bruising, pain, numbness and firmness after each session - and its labelled risks include marginal mandibular nerve injury, which causes an uneven smile, and difficulty swallowing. Usually up to six sessions, at least a month apart.

Because losing fat can make loose skin more obvious, these and a tightening treatment are sometimes considered together rather than as alternatives. That is a conversation to have with a provider who will examine you.

Before you book

Ultherapy does not break the skin, which removes a whole category of risk. If your plan involves anything that does break the skin - microneedling, radiofrequency microneedling, or an injectable treatment - tell the clinic at booking if you get cold sores. Antiviral medicine is started in advance, so it has to be prescribed before the appointment, not after a blister appears.

Get emergency help now

  • Fever with spreading redness, warmth or pus coming from a treated area. These are signs of a spreading infection and need urgent care the same day, not a routine appointment.

Call your provider if

  • Part of your face or neck looks hollow or deflated compared with the other side in the weeks after treatment
  • Your smile becomes uneven, or one side of your mouth does not move normally
  • Numbness, tingling or pain persists rather than settling over the days after treatment
  • A firm, well-defined lump develops in an area treated by cooling, two to six months afterwards
  • You were told a tightening treatment would reduce fat, and you want to check what was actually done
Questions people ask+
Does Ultherapy reduce fat?No. It is focused ultrasound aimed at connective tissue in the deeper layers, and fat reduction appears nowhere in what it is authorised to treat. Its indications describe lifting and the appearance of skin laxity.
Can Ultherapy get rid of a double chin?It is authorised to lift lax tissue beneath the chin and on the neck, which is a skin and support-layer effect. If the fullness under your chin is a fat pad rather than loose skin, that is a different problem, and cryolipolysis or deoxycholic acid injection are the treatments whose approved wording names submental fat.
Can Ultherapy cause facial fat loss?Subcutaneous fat atrophy is a documented rare adverse event of focused ultrasound. There is no published figure for how often it happens, whether it recovers, or what settings make it more likely - so it should be described as a real but unquantified risk, not a percentage.
How deep does Ultherapy go?Its transducers focus at roughly 1.5 mm, 3.0 mm and 4.5 mm below the surface. The 4.5 mm depth reaches the SMAS, the fibrous support layer under the face. The imaging function is separately authorised to visualise up to 8 mm down so the operator can confirm depth and avoid bone.
Is Ultherapy FDA approved?It was authorised through a De Novo request in 2009 and has been cleared several times since. Authorisation and clearance are marketing permissions based on meeting a regulatory standard - they are not a statement that the treatment works well for you, and they only cover the uses actually named.
What is the difference between Ultherapy and radiofrequency microneedling?Nothing breaks the skin with Ultherapy, and it can reach the SMAS. Radiofrequency microneedling puts needles through the skin and heats at a depth the operator chooses, which lets it treat surface texture and scarring but leaves an open channel. They are not two versions of the same treatment.
If I want less fullness under my chin, what should I ask at a consultation?Ask whether what you are seeing is loose skin, fat, a heavy platysma muscle band, or a combination - and ask which of those the proposed treatment acts on. That single question sorts out most mismatched treatment plans.
References+
FDA De Novo DEN080006, Ulthera System, decision 11 September 2009; device classification 21 CFR 878.4590, product code OHV. https://api.fda.gov/device/510k.json?search=k_number:DEN080006
The regulatory route that created the focused ultrasound aesthetic device category. The exact 2009 indication wording could not be retrieved from the FDA archive and is not quoted here.
FDA 510(k) K121700, Ulthera System, cleared 1 August 2012. https://www.accessdata.fda.gov/cdrh_docs/pdf12/K121700.pdf
The earliest Ultherapy indication wording retrievable from a primary FDA source: lift the eyebrow, and lift lax submental (beneath the chin) and neck tissue.
FDA 510(k) K180623, Ulthera System, cleared 4 May 2018. https://www.accessdata.fda.gov/cdrh_docs/pdf18/K180623.pdf
Source for the consolidated face and neck indication wording - lifting the eyebrow, lifting lax submental and neck tissue, improving lines and wrinkles of the decollete - and for the separately stated purpose of the imaging function.
FDA 510(k) K243035, Ulthera System, cleared 24 February 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K243035.pdf
Source for the addition of skin laxity on the abdomen and the anterior and posterior arms, and for the general statement about temporary changes in the physical appearance of the skin.
FDA 510(k) K134032, Ulthera System, cleared 20 June 2014. https://www.accessdata.fda.gov/cdrh_docs/pdf13/k134032.pdf
Source for the transducers used in testing, named by the frequency and focal depth convention that gives the 1.5 mm, 3.0 mm and 4.5 mm depths. The FDA document does not spell those depths out in millimetres.
FDA 510(k) K212707, CoolSculpting Elite System, cleared 5 November 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K212707.pdf
Source for the cold-assisted lipolysis indication, the named treatment areas and the body mass index limit.
Mah AE, Razeghi P, Li C, et al. Incidence of Paradoxical Adipose Hyperplasia After Cryolipolysis: A Systematic Review and Meta-Analysis. Aesthet Surg J Open Forum. 2025;7:ojaf142. https://pubmed.ncbi.nlm.nih.gov/41322038/
28 studies, 13,078 patients. Source for the pooled incidence of 0.22 per cent, about 1 in 455 patients, graded low-certainty, and for the observation that independent estimates exceed the manufacturer figure.
Nikolis A, et al. A Multicenter Evaluation of Paradoxical Adipose Hyperplasia Following Cryolipolysis. Aesthet Surg J. 2021;41(8):932-941. https://pubmed.ncbi.nlm.nih.gov/33216910/
2,114 patients and 8,658 cycles. The source in which the manufacturer-quoted rate of 0.025 per cent is reported as a manufacturer figure.
FDA drug label, KYBELLA (deoxycholic acid) injection, NDA 206333, approved 29 April 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206333s005lbl.pdf
Source for the submental fat indication, the limitation of use outside the submental region, and the labelled risks of marginal mandibular nerve injury and difficulty swallowing.
Chou M, Myers B, Avram M. Analysis of US Food and Drug Administration Data on Radiofrequency Microneedling Device Complications. Dermatol Surg. 2026 Mar 18, online ahead of print. https://pubmed.ncbi.nlm.nih.gov/41886649/
FDA MAUDE reports, January 2013 to October 2025: 114 reports containing 224 events, of which 26 were fat loss. Cited here only as context that fat loss is discussed after energy-based treatment. MAUDE is voluntary reporting with no denominator, so the figure is a proportion of reports and not a per-patient risk - and this analysis covers radiofrequency microneedling, not focused ultrasound.
← Back to Ultherapy